Martijn Lolkema
0000-0003-0466-2928
12 papers found
Refreshing results…
A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer
Predicting response to enzalutamide and abiraterone in metastatic prostate cancer using whole-omics machine learning
Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment
Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8+ T cells
The genomic landscape of 85 advanced neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets
Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cells
Radiotherapy is associated with a deletion signature that contributes to poor outcomes in patients with cancer
Author Correction: Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features
11-Ketotestosterone: the resilience of a potent androgen in prostate cancer patients after castration
Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features
The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact
The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies
Missing publications? Search for publications with a matching author name.